Skip to main content
UniHealth

Doctor search

Christopher Lock, MD

Neuropsychiatry · Stanford

NPI 1427205061

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lock’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A53673 · Current

Licensed to practise in California · since 1994 · expires 2028-08-31 · Far Eastern University, Dr. Nicanor Reyes Medical Foundation.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$36,244

Medicare paid this office $36,244 for 163 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)69$12,758$126
Long return visit (40+ min)45$8,844$164
New patient visit (60+ min)53$7,857$148
Return visit (30+ min)20$2,845$119
Return visit (30+ min)21$1,823$76
See all 6 services
Every Original Medicare service billed
Long return visit (40+ min)69$12,758$126
Long return visit (40+ min)45$8,844$164
New patient visit (60+ min)53$7,857$148
Return visit (30+ min)20$2,845$119
Return visit (30+ min)21$1,823$76
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or15$500$26

Who their Medicare patients are

163 Original Medicare patients in 2024. Average age 69 · Under 65 27% · 85 and older 10% · Women 66% · Also on Medicaid 28% · Health risk score 1.53. At or below the middle of the specialty; the typical neuropsychiatry clinician is at 1.55.

Conditions among them: High blood pressure 60% · Depression 28% · Diabetes 24% · Coronary heart disease 20% · Cancer 17% · Chronic kidney disease 15% · Atrial fibrillation 14% · Heart failure 13% · Stroke 12% · COPD 11% · Dementia 9%.

The office billed $119,982, Medicare allowed $48,014 and paid $36,244; for 286 services of 6 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024163286691.53$119,982$36,244
2023158336681.57$135,488$36,630
202277177621.57$87,543$17,974
202183183611.51$89,630$19,434
202084143601.62$53,365$10,231
201991147601.43$23,178$11,993
201887157641.43$20,475$12,645
2017119189641.37$47,004$16,795
2016112210641.80$63,192$20,049
2015169378711.33$77,430$22,491
2014266566741.17$158,100$44,652
2013270610741.34$157,140$45,034

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Original Medicare services billed in 2023
Long return visit (40+ min)99$22,009$124
New patient visit (60+ min)69$11,286$164
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or56$1,882$26

2022: 2 services

Original Medicare services billed in 2022
Long return visit (40+ min)69$14,880$125
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or33$1,292$29

2021: 3 services

Original Medicare services billed in 2021
Long return visit (40+ min)70$15,165$126
New patient visit (60+ min)14$2,400$171
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or26$1,011$30

2020: 2 services

Original Medicare services billed in 2020
Return visit (30+ min)39$4,127$66
Long return visit (40+ min)27$2,864$87

2019: 3 services

Original Medicare services billed in 2019
Return visit (30+ min)52$4,754$63
Long return visit (40+ min)34$3,760$84
New patient visit (60+ min)15$2,285$152

2018: 4 services

Original Medicare services billed in 2018
Long return visit (40+ min)39$4,533$86
Return visit (30+ min)38$3,477$59
New patient visit (60+ min)14$1,820$130
Long return visit (40+ min)14$1,496$100

2017: 4 services

Original Medicare services billed in 2017
Long return visit (40+ min)55$6,207$85
Return visit (30+ min)43$3,651$65
New patient visit (60+ min)28$3,467$124
New patient visit (45+ min)31$3,426$111

2016: 4 services

Original Medicare services billed in 2016
Long return visit (40+ min)61$8,783$90
New patient visit (60+ min)43$6,105$142
Return visit (30+ min)39$3,520$68
New patient visit (45+ min)14$1,500$107

2015: 6 services

Original Medicare services billed in 2015
Return visit (30+ min)57$4,938$77
New patient visit (45+ min)36$4,690$130
New patient visit (45+ min)37$4,282$116
Long return visit (40+ min)22$2,785$99
Return visit (30+ min)23$2,179$70
Long return visit (40+ min)16$1,956$115

2014: 3 services

Original Medicare services billed in 2014
New patient visit (45+ min)136$17,957$132
Return visit (30+ min)123$14,988$86
Long return visit (40+ min)65$9,434$119

2013: 4 services

Original Medicare services billed in 2013
New patient visit (45+ min)161$21,631$134
Return visit (30+ min)114$14,784$86
Long return visit (40+ min)41$4,975$121
Short return visit (20+ min)23$1,506$58

Medicaid work

$512 in 2024

Medicaid paid $512 for 14 billed services this clinician did in 2024, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)14$512
Medicaid work by year
202414113$512
202338113$2,097
202224112$1,735
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)38$2,097

2022

Largest Medicaid services in 2022
Long return visit (40+ min)24$1,735

Drugs they prescribed that Part D paid

$583,233

Pharmacies billed $583,233 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

360 generic and 52 brand-name prescriptions · $583,233 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Kesimpta35$372,034$10,630
Dalfampridine Er29$4,980$172
Baclofen54$2,677$50
Oxcarbazepine16$1,415$88
Gabapentin70$1,271$18
See all 8 drugs
Every Part D drug this clinician prescribed
Kesimpta35$372,034$10,630
Dalfampridine Er29$4,980$172
Baclofen54$2,677$50
Oxcarbazepine16$1,415$88
Gabapentin70$1,271$18
Pregabalin25$1,169$47
Levetiracetam18$710$39
Carbidopa-Levodopa14$237$17

Year by year

Part D prescribing by year
202441284None13%$583,233
202337772NoneNone$280,425
202239052None8%$242,298
202151659None17%$605,742
202060366None24%$1,102,702
201964966None27%$1,215,894
2018620570% (0)41%$1,431,998
201741758None42%$1,112,319
2016383603% (12)37%$751,536
2015510118None22%$191,342
20148471322% (17)None$259,826
2013829135None26%$264,839

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 9 drugs

Part D drugs prescribed in 2023
Kesimpta15$190,986$12,732
Dalfampridine Er41$10,199$249
Modafinil28$3,208$115
Oxcarbazepine20$2,014$101
Baclofen36$1,861$52
Gabapentin65$1,565$24
Pregabalin25$971$39
Lamotrigine14$421$30
Ibuprofen16$27$2

2022: 9 drugs

Part D drugs prescribed in 2022
Copaxone22$129,335$5,879
Dalfampridine Er51$17,331$340
Carbamazepine Er15$4,698$313
Baclofen43$3,195$74
Modafinil18$2,980$166
Gabapentin65$2,099$32
Pregabalin46$1,962$43
Oxcarbazepine24$1,430$60
Lamotrigine13$222$17

2021: 17 drugs

Part D drugs prescribed in 2021
Tecfidera23$199,544$8,676
Aubagio18$150,621$8,368
Copaxone20$123,596$6,180
Dimethyl20$66,766$3,338
Dalfampridine Er79$25,482$323
Baclofen72$5,723$79
Carbamazepine Er21$3,547$169
Gabapentin58$1,800$31
Modafinil21$1,675$80
Duloxetine17$1,554$91
Pregabalin27$1,071$40
Dextroamphetamine-Amphetamine12$602$50
Oxcarbazepine13$547$42
Topiramate11$166$15
Escitalopram11$149$14
Diazepam13$130$10
Clonazepam11$69$6

2020: 13 drugs

Part D drugs prescribed in 2020
Tecfidera54$461,372$8,544
Aubagio39$310,949$7,973
Copaxone24$144,424$6,018
Dimethyl11$63,545$5,777
Dalfampridine Er87$61,396$706
Baclofen86$4,443$52
Carbamazepine Er14$3,857$275
Gabapentin87$2,562$29
Pregabalin23$2,213$96
Duloxetine31$1,833$59
Dextroamphetamine-Amphetamine11$858$78
Levetiracetam20$368$18
Topiramate15$225$15

2019: 15 drugs

Part D drugs prescribed in 2019
Tecfidera56$452,867$8,087
Aubagio34$282,921$8,321
Gilenya17$148,973$8,763
Copaxone24$141,436$5,893
Dalfampridine Er82$51,863$632
Lyrica19$12,785$673
Baclofen78$3,197$41
Gabapentin89$2,588$29
Levetiracetam21$1,312$62
Modafinil11$1,070$97
Dextroamphetamine-Amphetamine16$1,038$65
Propranolol17$516$30
Duloxetine13$326$25
Topiramate19$230$12
Bupropion Hcl Sr11$159$14

2018: 15 drugs

Part D drugs prescribed in 2018
Aubagio71$563,600$7,938
Tecfidera48$363,960$7,583
Ampyra68$199,600$2,935
Gilenya17$133,249$7,838
Copaxone12$70,928$5,911
Dalfampridine Er19$16,794$884
Baclofen74$2,868$39
Levetiracetam23$1,309$57
Gabapentin40$1,081$27
Propranolol24$414$17
Duloxetine13$363$28
Tizanidine13$281$22
Escitalopram23$259$11
Oxybutynin Chloride12$217$18
Ropinirole11$45$4

2017: 13 drugs

Part D drugs prescribed in 2017
Aubagio41$384,328$9,374
Tecfidera44$309,163$7,026
Gilenya23$165,327$7,188
Ampyra53$135,902$2,564
Memantine14$1,065$76
Baclofen46$1,060$23
Levetiracetam17$487$29
Oxybutynin Chloride12$395$33
Gabapentin17$315$19
Propranolol12$184$15
Escitalopram17$184$11
Amitriptyline11$131$12
Cyclobenzaprine12$86$7

2016: 13 drugs

Part D drugs prescribed in 2016
Gilenya42$281,065$6,692
Aubagio22$207,458$9,430
Ampyra40$114,566$2,864
Tecfidera15$97,021$6,468
Baclofen30$550$18
Donepezil29$370$13
Levetiracetam22$328$15
Carbidopa-Levodopa14$284$20
Bupropion Hcl Sr11$279$25
Oxybutynin Chloride13$272$21
Gabapentin17$199$12
Lorazepam19$113$6
Escitalopram11$35$3

2015: 15 drugs

Part D drugs prescribed in 2015
Ampyra11$23,516$2,138
Namenda25$9,913$397
Lyrica14$6,319$451
Rivastigmine12$2,848$237
Carbidopa-Levodopa42$1,639$39
Baclofen12$690$57
Levetiracetam13$584$45
Donepezil41$574$14
Gabapentin26$460$18
Quetiapine21$320$15
Lamotrigine21$270$13
Topiramate19$173$9
Clonazepam20$166$8
Propranolol11$141$13
Clopidogrel13$122$9

2014: 25 drugs

Part D drugs prescribed in 2014
Tecfidera16$81,251$5,078
Copaxone12$61,155$5,096
Namenda50$20,414$408
Exelon30$14,173$472
Rivastigmine28$6,697$239
Depakote12$5,930$494
Carbidopa-Levodopa77$4,757$62
Dextroamphetamine Sulfate Er11$2,893$263
Selegiline16$1,737$109
Levetiracetam32$1,420$44
Donepezil73$1,166$16
Zonisamide12$756$63
Lamotrigine29$599$21
Gabapentin22$485$22
Baclofen15$481$32
Topiramate24$414$17
Carbidopa-Levodopa Er17$402$24
Quetiapine21$387$18
Clonazepam44$326$7
Amitriptyline28$304$11
Clopidogrel23$272$12
Escitalopram11$170$15
Nortriptyline12$121$10
Propranolol12$119$10
Zolpidem12$73$6

2013: 22 drugs

Part D drugs prescribed in 2013
Copaxone23$108,809$4,731
Namenda88$30,529$347
Exelon31$9,475$306
Rivastigmine26$7,381$284
Depakote12$5,268$439
Carbidopa-Levodopa78$5,136$66
Donepezil89$1,745$20
Levetiracetam51$1,570$31
Carbamazepine Xr11$1,257$114
Selegiline11$1,118$102
Quetiapine23$979$43
Ropinirole12$818$68
Clopidogrel32$715$22
Gabapentin19$460$24
Carbidopa-Levodopa Er16$342$21
Topiramate17$249$15
Nortriptyline12$248$21
Clonazepam24$246$10
Sertraline21$241$11
Amitriptyline23$116$5
Meclizine12$102$9
Citalopram Hbr13$66$5

Money from drug and device companies

$12,341 in 2025

Industry payments by year
2025216$11,000$12,341
2024417$9,350$20,624
202313$2,050$2,073
202213$3,600$3,600
202146$8,368$8,368
2020543$26,766$30,703
2019690$71,740$81,327

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AmgenUplizna$12,315
15 payments
  • Paid to speak or teach for Uplizna · 2025-11-25 · $3,300
  • Meals for Uplizna · 2025-11-06 · $31
  • Meals for Uplizna · 2025-11-05 · $121
  • Paid to speak or teach for Uplizna · 2025-05-20 · $3,300
  • Paid to speak or teach for Uplizna · 2025-05-20 · $3,300
  • Paid to speak or teach for Uplizna · 2025-05-20 · $550
  • Paid to speak or teach for Uplizna · 2025-05-20 · $550
  • Travel for Uplizna · 2025-05-19 · $49
  • Travel for Uplizna · 2025-05-19 · $179
  • Travel for Uplizna · 2025-05-19 · $8
  • Travel for Uplizna · 2025-05-19 · $49
  • Travel for Uplizna · 2025-05-19 · $179
  • Travel for Uplizna · 2025-05-19 · $8
  • Travel for Uplizna · 2025-05-03 · $345
  • Travel for Uplizna · 2025-05-03 · $345
BiogenTysabri$26
1 payment
  • Meals for Tysabri · 2025-04-24 · $26
See all 16 published payments
Every published payment
AmgenPaid to speak or teach · 2025-11-25Uplizna$3,300
AmgenMeals · 2025-11-06Uplizna$31
AmgenMeals · 2025-11-05Uplizna$121
AmgenPaid to speak or teach · 2025-05-20Uplizna$3,300
AmgenPaid to speak or teach · 2025-05-20Uplizna$3,300
AmgenPaid to speak or teach · 2025-05-20Uplizna$550
AmgenPaid to speak or teach · 2025-05-20Uplizna$550
AmgenTravel · 2025-05-19Uplizna$49
AmgenTravel · 2025-05-19Uplizna$179
AmgenTravel · 2025-05-19Uplizna$8
AmgenTravel · 2025-05-19Uplizna$49
AmgenTravel · 2025-05-19Uplizna$179
AmgenTravel · 2025-05-19Uplizna$8
AmgenTravel · 2025-05-03Uplizna$345
AmgenTravel · 2025-05-03Uplizna$345
BiogenMeals · 2025-04-24Tysabri$26
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $20,624

Payments by company in 2024
AmgenUplizna$10,870
11 payments
  • Paid to speak or teach · 2024-12-23 · $1,650
  • Paid to speak or teach for Uplizna · 2024-11-12 · $3,300
  • Meals for Uplizna · 2024-10-30 · $125
  • Travel for Uplizna · 2024-06-03 · $126
  • Travel for Uplizna · 2024-06-03 · $29
  • Travel for Uplizna · 2024-06-03 · $88
  • Paid to speak or teach for Uplizna · 2024-05-13 · $1,100
  • Paid to speak or teach for Uplizna · 2024-05-13 · $3,300
  • Travel for Uplizna · 2024-05-03 · $388
  • Travel for Uplizna · 2024-05-01 · $376
  • Travel for Uplizna · 2024-04-16 · $388
Roche ProductsNone$9,632
4 payments
  • Travel · 2024-06-25 · $401
  • Meals · 2024-06-25 · $135
  • Travel · 2024-06-25 · $129
  • Travel · 2024-06-25 · $8,967
GenzymeNone$103
1 payment
  • Meals · 2024-03-07 · $103
CelgeneZeposia$19
1 payment
  • Meals for Zeposia · 2024-02-29 · $19

2023: $2,073

Payments by company in 2023
Horizon Therapeutics plcUplizna$2,073
3 payments
  • Meals for Uplizna · 2023-12-08 · $23
  • Honoraria for Uplizna · 2023-12-07 · $400
  • Honoraria for Uplizna · 2023-08-18 · $1,650

2022: $3,600

Payments by company in 2022
E.R. Squibb & Sons L.L.C.Zeposia$3,600
3 payments
  • Paid to speak or teach for Zeposia · 2022-11-09 · $1,200
  • Paid to speak or teach for Zeposia · 2022-10-19 · $1,200
  • Paid to speak or teach for Zeposia · 2022-10-04 · $1,200

2021: $8,368

Payments by company in 2021
Greenwich BiosciencesNone$3,808
1 payment
  • Consulting · 2021-10-28 · $3,808
E.R. Squibb & Sons L.L.C.Zeposia$2,400
2 payments
  • Paid to speak or teach for Zeposia · 2021-12-20 · $1,200
  • Paid to speak or teach · 2021-12-07 · $1,200
GenentechOcrevus$1,260
1 payment
  • Consulting for Ocrevus · 2021-05-19 · $1,260
CelgeneZeposia$900
2 payments
  • Paid to speak or teach for Zeposia · 2021-05-09 · $300
  • Paid to speak or teach for Zeposia · 2021-03-27 · $600

2020: $30,703

Payments by company in 2020
BiogenTysabri$15,547
17 payments
  • Paid to speak or teach · 2020-09-22 · $2,625
  • Travel for Tysabri · 2020-01-11 · $344
  • Travel for Tysabri · 2020-01-11 · $30
  • Travel for Tysabri · 2020-01-11 · $17
  • Travel for Tysabri · 2020-01-11 · $48
  • Consulting for Tysabri · 2020-01-11 · $11,682
  • Travel for Tysabri · 2020-01-11 · $36
  • Meals for Tysabri · 2020-01-11 · $59
  • Meals for Tysabri · 2020-01-11 · $117
  • Meals for Tysabri · 2020-01-11 · $89
  • Travel for Tysabri · 2020-01-10 · $30
  • Meals for Tysabri · 2020-01-10 · $13
  • Travel for Tysabri · 2020-01-10 · $17
  • Travel for Tysabri · 2020-01-10 · $102
  • Travel for Tysabri · 2020-01-10 · $197
  • Meals for Tysabri · 2020-01-10 · $17
  • Meals for Tysabri · 2020-01-10 · $125
CelgeneZeposia$7,283
12 payments
  • Paid to speak or teach for Zeposia · 2020-08-27 · $1,680
  • Paid to speak or teach for Zeposia · 2020-06-20 · $480
  • Travel for Zeposia · 2020-02-22 · $992
  • Travel for Zeposia · 2020-02-22 · $260
  • Paid to speak or teach for Zeposia · 2020-02-22 · $3,600
  • Meals for Zeposia · 2020-02-22 · $60
  • Meals for Zeposia · 2020-02-22 · $29
  • Meals for Zeposia · 2020-02-22 · $8
  • Meals for Zeposia · 2020-02-22 · $50
  • Meals for Zeposia · 2020-02-22 · $60
  • Travel for Zeposia · 2020-02-22 · $18
  • Meals for Zeposia · 2020-02-22 · $45
GenzymeAubagio$6,914
11 payments
  • Paid to speak or teach for Aubagio · 2020-02-28 · $2,725
  • Travel for Aubagio · 2020-02-08 · $439
  • Travel for Aubagio · 2020-02-08 · $70
  • Travel for Aubagio · 2020-02-08 · $214
  • Paid to speak or teach for Aubagio · 2020-02-08 · $3,114
  • Meals for Aubagio · 2020-02-08 · $15
  • Travel for Aubagio · 2020-02-08 · $101
  • Travel for Aubagio · 2020-02-08 · $45
  • Travel for Aubagio · 2020-02-08 · $9
  • Meals for Aubagio · 2020-02-08 · $60
  • Meals for Aubagio · 2020-02-08 · $122
EMD SeronoMavenclad$869
2 payments
  • Meals for Mavenclad · 2020-03-10 · $9
  • Paid to speak or teach for Mavenclad · 2020-02-03 · $860
Sanofi-Aventis U.S.Lemtrada$91
1 payment
  • Education for Lemtrada · 2020-10-23 · $91

2019: $81,327

Payments by company in 2019
BiogenTecfidera$40,975
29 payments
  • Paid to speak or teach for Tecfidera · 2019-12-19 · $3,150
  • Travel for Tecfidera · 2019-12-05 · $527
  • Paid to speak or teach for Tecfidera · 2019-12-05 · $4,200
  • Meals for Tecfidera · 2019-12-05 · $50
  • Paid to speak or teach · 2019-11-19 · $4,200
  • Travel · 2019-11-19 · $632
  • Meals · 2019-11-19 · $47
  • Travel for Tecfidera · 2019-07-09 · $527
  • Paid to speak or teach for Tecfidera · 2019-07-09 · $3,675
  • Consulting · 2019-04-12 · $7,744
  • Paid to speak or teach for Tecfidera · 2019-03-26 · $3,675
  • Meals for Tecfidera · 2019-03-26 · $125
  • Travel · 2019-03-23 · $36
  • Meals · 2019-03-23 · $70
  • Travel · 2019-03-23 · $41
  • Meals · 2019-03-23 · $36
  • Meals · 2019-03-23 · $39
  • Meals · 2019-03-23 · $81
  • Travel · 2019-03-22 · $463
  • Travel · 2019-03-22 · $169
  • Travel · 2019-03-22 · $101
  • Meals · 2019-03-22 · $135
  • Travel · 2019-03-22 · $42
  • Paid to speak or teach for Tysabri · 2019-03-13 · $3,675
  • Meals for Tysabri · 2019-03-13 · $42
  • Paid to speak or teach for Tecfidera · 2019-02-05 · $3,675
  • Meals for Tecfidera · 2019-02-05 · $42
  • Paid to speak or teach for Tecfidera · 2019-01-22 · $3,675
  • Meals for Tecfidera · 2019-01-22 · $104
GenzymeAubagio$18,824
28 payments
  • Travel for Aubagio · 2019-11-02 · $271
  • Travel for Aubagio · 2019-11-02 · $242
  • Travel for Aubagio · 2019-11-02 · $56
  • Meals for Aubagio · 2019-11-02 · $140
  • Meals for Aubagio · 2019-11-02 · $50
  • Meals for Aubagio · 2019-11-02 · $100
  • Meals for Aubagio · 2019-11-02 · $70
  • Meals for Aubagio · 2019-11-02 · $27
  • Travel for Aubagio · 2019-11-02 · $60
  • Travel for Aubagio · 2019-11-02 · $18
  • Consulting for Aubagio · 2019-11-02 · $7,785
  • Meals for Aubagio · 2019-09-04 · $25
  • Paid to speak or teach for Aubagio · 2019-09-04 · $2,573
  • Meals for Aubagio · 2019-09-03 · $25
  • Paid to speak or teach for Aubagio · 2019-09-03 · $2,573
  • Meals for Aubagio · 2019-08-07 · $83
  • Meals for Aubagio · 2019-07-31 · $3
  • Travel for Aubagio · 2019-01-26 · $236
  • Meals for Aubagio · 2019-01-26 · $143
  • Travel for Aubagio · 2019-01-26 · $114
  • Meals for Aubagio · 2019-01-26 · $66
  • Meals for Aubagio · 2019-01-26 · $86
  • Meals for Aubagio · 2019-01-26 · $44
  • Consulting for Aubagio · 2019-01-26 · $3,675
  • Travel for Aubagio · 2019-01-26 · $72
  • Travel for Aubagio · 2019-01-26 · $23
  • Travel for Aubagio · 2019-01-26 · $206
  • Travel for Aubagio · 2019-01-26 · $60
CelgeneOzanimod$8,054
8 payments
  • Consulting for Ozanimod · 2019-09-06 · $6,720
  • Meals for Ozanimod · 2019-08-01 · $40
  • Travel for Ozanimod · 2019-08-01 · $204
  • Travel for Ozanimod · 2019-08-01 · $133
  • Travel for Ozanimod · 2019-08-01 · $847
  • Meals for Ozanimod · 2019-08-01 · $30
  • Meals for Ozanimod · 2019-08-01 · $50
  • Meals for Ozanimod · 2019-08-01 · $30
EMD SeronoMavenclad$7,677
8 payments
  • Travel for Mavenclad · 2019-06-04 · $95
  • Meals for Mavenclad · 2019-06-04 · $6
  • Paid to speak or teach for Mavenclad · 2019-05-29 · $6,665
  • Meals for Mavenclad · 2019-04-15 · $3
  • Meals for Mavenclad · 2019-04-15 · $1
  • Travel for Mavenclad · 2019-04-13 · $554
  • Travel for Mavenclad · 2019-04-13 · $234
  • Meals · 2019-03-20 · $119
Alexion PharmaceuticalsSoliris$5,487
12 payments
  • Meals · 2019-12-11 · $122
  • Meals for Soliris · 2019-08-29 · $121
  • Meals for Soliris · 2019-07-12 · $6
  • Meals · 2019-06-22 · $23
  • Meals · 2019-06-22 · $34
  • Travel · 2019-06-22 · $37
  • Meals · 2019-06-22 · $47
  • Meals · 2019-06-22 · $49
  • Paid to speak or teach · 2019-06-22 · $4,080
  • Meals · 2019-06-21 · $121
  • Travel · 2019-06-21 · $206
  • Travel · 2019-06-21 · $641
Novartis PharmaceuticalsGilenya$310
5 payments
  • Meals for Mayzent · 2019-09-12 · $27
  • Meals for Gilenya · 2019-05-30 · $61
  • Meals for Gilenya · 2019-02-27 · $106
  • Meals for Gilenya · 2019-01-18 · $106
  • Meals for Gilenya · 2019-01-08 · $10

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
UCB SA · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With An Open-Lable Extension Period To Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (Mog) Antibody-Associated Disease (Mog-Ad) · 2025Their institution$388,332
Genentech, Inc. · Mnt Oboe · 2019Their institution$129,387
GENZYME CORPORATION · A Randomized, Double-Blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (Sar441344) To Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis · 2025Their institution$122,743
Genentech, Inc. · Mnt Oboe · 2023Their institution$66,376
AbbVie Inc. · 2020Their institution$62,411
Genentech, Inc. · Mnt Oboe · 2021Their institution$55,432
Genentech, Inc. · Mnt Oboe · 2020Their institution$52,240
UCB SA · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With An Open-Lable Extension Period To Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (Mog) Antibody-Associated Disease (Mog-Ad) · 2024Their institution$50,912
Genentech, Inc. · Mnt Oboe · 2022Their institution$49,748
AbbVie, Inc. · 2019Their institution$27,722
Mallinckrodt Enterprises LLC · A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study To Assess the Efficacy and Safety of H.P. Acthar Gel in the Subjects With Relapsing-Remitting Multiple Sclerosis · 2019Their institution$26,708
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis · 2019Their institution$20,813
Mallinckrodt Hospital Products Inc. · A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study To Assess the Efficacy and Safety of H.P. Acthar Gel in the Subjects With Relapsing-Remitting Multiple Sclerosis · 2020Their institution$18,885
ABBVIE INC. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study To Assess the Safety and Efficacy of Elezanumab When Added To Standard of Care in Progressive Forms of Multiple Sclerosis · 2021Their institution$15,040
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis · 2020Their institution$14,967
Genentech, Inc. · First in Human Study Ro7121932 · 2024Their institution$14,231
Genentech, Inc. · First in Human Study Ro7121932 · 2023Their institution$12,336
ABBVIE INC. · A Study To Assess the Safety and Efficacy of Elezanumab When Added To Standard of Care in Progressive Forms of Multiple Sclerosis · 2022Their institution$10,932
ABBVIE INC. · A Study To Assess the Safety and Efficacy of Elezanumab When Added To Standard of Care in Relapsing Forms of Multiple Sclerosis · 2022Their institution$10,420
Genentech, Inc. · First in Human Study Ro7121932 · 2025Their institution$7,103
Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib · 2022Their institution$3,477
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (Sar441344) To Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis · 2024This clinician$2,788
Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib · 2024Their institution$238
Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib · 2023Their institution$205

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1427205061
Licence
CA A53673California A53673: Current · expires 2028-08-31
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 2084N0600X (2084N0600X); Neurology (2084N0400X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2008-08-26
NPI last updated
2023-11-10
NPI record certified
2023-11-10

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 795 El Camino Real, Palo Alto, CA, 94301